COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-001527-14-NL


Column Value
Trial registration number EUCTR2020-001527-14-NL
Full text link
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

First author
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Erasmus MC - J.G.J.V. Aerts

Contact
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

j.aerts@erasmusmc.nl

Registration date
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2020-04-06

Recruitment status
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Recruiting

Study design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Open label

Center
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

single-center

Study aim
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Proven diagnosis of COVID-19 by positive PCR in any specimen < 48 hours prior to randomization. Age ≥ 18 year Hospitalized patients with illness of any duration, and SpO2 ≤ 94% on room air Proven diagnosis of COVID-19 by positive PCR in any specimen < 48 hours prior to randomization. Age ≥ 18 year Hospitalized patients with illness of any duration, and SpO2 ≤ 94% on room air

Exclusion criteria
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Severe hypoxemic respiratory failure expected to die < 72 hours after admission ICU admission < 72 hours Allergy for chloroquine or azithromycin Pregnancy QT-prolongation: pre-existent: QTc males >450ms, QTc females > 470ms at day 1 and at day 2 Myasthenia gravis Epilepsy Severe hypoxemic respiratory failure expected to die < 72 hours after admission ICU admission < 72 hours Allergy for chloroquine or azithromycin Pregnancy QT-prolongation: pre-existent: QTc males >450ms, QTc females > 470ms at day 1 and at day 2 Myasthenia gravis Epilepsy

Number of arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Erasmus MC

Inclusion age min
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

None

Countries
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Netherlands

Type of patients
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Moderate/severe disease at enrollment

Severity scale
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

4: Moderate/severe disease at enrollment

Total sample size
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

60

primary outcome
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

The initial response to treatment will be evaluated during admission. Cure is considered when 3 criteria are present: (1) O2 sat > 94% with room air (2) 24 hours without fever (≥38°C) (3) Breathing frequency < 24/min The percentage of patients with clinical cure at day 7 will be calculated The initial response to treatment will be evaluated during admission. Cure is considered when 3 criteria are present: (1) O2 sat > 94% with room air (2) 24 hours without fever (≥38°C) (3) Breathing frequency < 24/min The percentage of patients with clinical cure at day 7 will be calculated

Notes
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

nan

Phase
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

Phase 4

Arms
Last imported at : Oct. 26, 2020, 7:26 a.m.
Source : EU Clinical Trials Register

[{"arm_notes": "", "treatment_id": 279, "treatment_name": "Chloroquine", "treatment_type": "Antimalarials", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1454, "treatment_name": "Azithromycin+chloroquine", "treatment_type": "Antibiotics+antimalarials", "pharmacological_treatment": "Pharmacological treatment"}]